HEMK2 CRISPR/Cas9 KO Plasmid (h): sc-406503
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HEMK2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the HEMK2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: HEMK2 Antibody (1C4): sc-517120
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HEMK2 CRISPR/Cas9 KO Plasmid (h) | sc-406503 | 20 µg | $397.00 |
Overview
N6AMT1 (also known as HEMK2) encodes a methyltransferase that catalyzes protein methylation, contributing to regulation of translational fidelity and ribosome-associated processes. HEMK2 has been linked to methylation of translation termination and ribosomal components, connecting it to proteostasis pathways and cellular stress responses that depend on accurate protein synthesis. Altered N6AMT1/HEMK2 activity has been studied in contexts involving genome stability, mitochondrial and oxidative stress signaling, and dysregulated growth control, making it relevant for mechanistic work in cancer biology and other disorders characterized by perturbed proteome maintenance. Its enzymatic function and broad cellular integration support its use as a node for investigating post-translational modification networks and downstream transcriptional and metabolic adaptations.
HEMK2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the N6AMT1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the N6AMT1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the N6AMT1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HEMK2 protein expression.
This CRISPR knockout system enables efficient generation of N6AMT1-deficient cell models for investigation of HEMK2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting N6AMT1 exon(s) critical for HEMK2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple N6AMT1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by HEMK2 CRISPR/Cas9 KO Plasmid (h) and HEMK2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the N6AMT1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by HEMK2 HDR Plasmid (h) and HEMK2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by N6AMT1 homology arms to support homology-directed repair at defined N6AMT1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.